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Abstract
Background: Network meta-analysis, a method to synthesise evidence from multiple treatments, has increased in
popularity in the past decade. Two broad approaches are available to synthesise data across networks, namely, arm-
and contrast-synthesis models, with a range of models that can be fitted within each. There has been recent
debate about the validity of the arm-synthesis models, but to date, there has been limited empirical evaluation
comparing results using the methods applied to a large number of networks. We aim to address this gap
through the re-analysis of a large cohort of published networks of interventions using a range of network
meta-analysis methods.
Methods: We will include a subset of networks from a database of network meta-analyses of randomised
trials that have been identified and curated from the published literature. The subset of networks will include
those where the primary outcome is binary, the number of events and participants are reported for each
direct comparison, and there is no evidence of inconsistency in the network. We will re-analyse the networks
using three contrast-synthesis methods and two arm-synthesis methods. We will compare the estimated
treatment effects, their standard errors, treatment hierarchy based on the surface under the cumulative
ranking (SUCRA) curve, the SUCRA value, and the between-trial heterogeneity variance across the network
meta-analysis methods. We will investigate whether differences in the results are affected by network
characteristics and baseline risk.
Discussion: The results of this study will inform whether, in practice, the choice of network meta-analysis
method matters, and if it does, in what situations differences in the results between methods might arise.
The results from this research might also inform future simulation studies.
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Background
Network meta-analysis (NMA) (also referred to as mixed
treatment comparisons or multiple treatment compari-
sons) is the quantitative component of a review that
combines direct and indirect evidence across a network
of treatments [1]. NMA has many potential benefits
compared with pairwise meta-analysis, with one particu-
lar advantage being the ability to rank a set of competing
treatments according to their safety or effectiveness, or
both, thus facilitating clinical decision-making [2]. The
use of NMA methods has become increasingly common
[3], alongside methodological developments (see, for
example, Efthimiou et al. [4] for a recent review of NMA
methodology), tutorial papers explaining the methods
(e.g. [5, 6]), and user written packages/routines in Stata,
R, and WinBUGS/OpenBUGS (e.g. [4, 7]).
Two broad approaches have been proposed for the
synthesis of evidence across networks. In the first
approach, the trial-specific relative treatment effects (e.g.
log of the odds ratio) over the trials are pooled (hence-
forth referred to as contrast-synthesis models), whereas
in the second approach, the absolute estimates (e.g. log
odds) of each arm are pooled and treatment effects (e.g.
odds ratios, risk differences) are constructed from the
arm estimates (henceforth referred to as arm-synthesis
models) [8]. Detailed explanations of these models have
been published [2, 8–11] and brief explanations are pro-
vided below. There has been recent debate about the
validity of the arm-synthesis models [8, 10, 12]; propo-
nents argue that they offer an advantage to standard
methods because they allow the analyst to estimate both
relative and absolute measures [13]. However, opponents
argue that these methods represent a departure from
standard meta-analysis practice as they compromise the
advantage of randomisation by relating arms across
studies [8].
A common assumption that is made under the random-
effects contrast-synthesis model is that the between-trial
heterogeneity variance of the relative treatment effects is
the same for every treatment comparison [2, 4]. This
assumption, referred to as the ‘homogeneous variance
assumption’ [14] reduces the number of parameters that
need to be estimated, simplifies the estimation and
increases the precision for estimating the heterogeneity
variance [4]. However, even with this assumption, the
available data in the network may be limited for estimat-
ing the heterogeneity variance. The Bayesian framework
for fitting the contrast-synthesis model offers the oppor-
tunity of incorporating external estimates of heterogen-
eity, such as those estimated from large empirical data
sets, which may improve precision in the estimation of the
heterogeneity variance [15]. Turner et al. [16] provide
informative prior distributions defined by outcome type
and intervention comparison [16, 17].
Evidence about the relative merits and drawbacks of
statistical methods comes from statistical theory, numer-
ical simulation studies, and empirical evaluation. Simula-
tion studies allow investigation of the performance of
statistical methods against a known truth [18], and are
useful for exploring the properties of the methods (e.g.
Song et al. [19]), particularly in scenarios where the
assumptions of the underlying methods may not be met.
Empirical studies allow investigation of how methods
work in practice using actual data (e.g. Langan et al.
[20]), and in particular, allow estimation of the magni-
tude of discordance in results between the methods, and
exploration of factors that might predict this discord-
ance. To facilitate both simulation studies and empirical
research on NMA methods, a dataset of 456 NMAs
containing available data from all published NMAs since
1999 has been compiled [21].
To our knowledge, no study has empirically compared
the results of NMA between the contrast-synthesis and
arm-synthesis models across a large number of networks.
In this study, we will achieve this through the re-analysis
of published networks of interventions with binary out-
comes using five NMA models.
Methods/design
Database of networks
We will use a database of 456 published NMAs of
randomised trials that have been previously identified
and curated. Details of the methods for locating the
NMA publications, inclusion criteria, and the screening
process are outlined in Petropoulou et al. [21]. The
database compares networks with at least four different
interventions that employed an appropriate synthesis
method. The data extracted from the networks (of im-
portance for the present study) included publication
characteristics (e.g. year of publication, journal of publi-
cation); summary statistics (e.g. number of events and
number of participants per arm) from the direct compari-
sons of the primary NMA outcome in the review (or the
outcome identified from a decision tree when no primary
outcome was specified [21]; classification of the outcome
in terms of whether it was harmful or beneficial, and
whether it was an objective, semi-objective, or subjective
measure; and whether the type of included treatment
comparisons were pharmacological vs placebo, pharmaco-
logical vs pharmacological or non-pharmacological vs any
intervention.
Eligibility criteria for the present study
We will include a subset of networks from the database
which meet the following inclusion criteria: (i) a binary
primary outcome, (ii) the number of events and number
of participants are available for each trial arm, and (iii)
for networks including at least one closed loop, there is
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no evidence of statistical inconsistency as detected by a
p value <0.10 via the design by treatment interaction test
using Stata’s mvmeta command [22]. Tests for the
evaluation of the consistency of a network, for example,
the design by treatment interaction, are known to have
low power, which led us to choose a p value of 0.10 as
our cut-off [19, 23].
Statistical methods to analyse the networks
We will begin by describing the notation, then describe
the contrast-synthesis models, followed by a brief de-
scription of the arm-synthesis models. Details about the
estimation methods and packages used to fit the models
in R are described in the section ‘Implementing the
models in R’ below.
In the following, we assume that there are I studies in
the network (labelled i = 1, 2, …, I) and that each study
investigates a subset of the K treatments. The studies are
labelled k = 1, 2, …, K and the subset of treatments com-
pared in study i is denoted Si. We further assume that in
study i, the observed number of events, yik, has arisen
from a binomial process, yik ~ bin(nik,pik), where nik is
the number of participants in arm k k∈Sið Þ , and pik is
the probability of the event.
Contrast-synthesis models
In the contrast-synthesis model, a baseline treatment b
(usually placebo or standard of care) is specified for each
study i. The hierarchical model for this approach is
g pikð Þ ¼ μi þ Xikδibk ; k∈Si
δibk
e
N θbk ; τ
2
bk
 
;
where g ∙ð Þ is the logit link, μi are the study-specific base-
line effects and will be treated as unrelated nuisance pa-
rameters, δibk represents the study-specific effect of
treatment k relative to the baseline b and Xik is an indi-
cator variable which is set to 0 if k = b and 1 otherwise.
The study-specific treatment effects δibk are drawn from
a common random-effects distribution, where θbk repre-
sents the mean effect of treatment k, relative to the base-
line treatment, and τ2bk represents the between-trial
variance in treatment effects. Finally, we make the
consistency assumption that if any two treatments, say x
and y, are compared indirectly through b, the result will
be consistent with the direct comparison; that is: θxy
= θbx − θby. For multi-arm trials, an adjustment is re-
quired where δibk is assumed to be multivariate normally
distributed [2]. Implementation of models with a bino-
mial likelihood is possible in either a frequentist or
Bayesian framework but these are easier to estimate in a
Bayesian framework [2]. For this reason, we will use a
Bayesian framework to fit the variants of this model (see
the section ‘Contrast-synthesis models in a Bayesian
framework’).
An alternative contrast-synthesis approach is to model
the estimates of the treatment contrasts. First, let Y ibk
¼ log pik= 1pikð Þpib= 1pibð Þ
 
denote the log odds ratio for treatment
k relative to the baseline b in trial i, the model here is
then:
Y ibk
e
N δibk ; σ
2
ibk
 
where σ2ibk is the variance of the log odds ratio and δibk
is drawn from the common random-effects distribution
above. We will implement this model in a frequentist
framework (see section ‘Contrast-synthesis model in a
frequentist framework’).
Arm-synthesis models
The arm-synthesis model is specified such that:
Φ−1 pikð Þ ¼ μk þ vik ; k∈Si
vi1; vi2 ;…; viKð ÞT
e
MVN 0;ΣKð Þ;
where Φ ∙ð Þ is the standard normal cumulative distribu-
tion function. The log link function can also be used
[10]. The μk’ s are fixed effects for the treatments, and
the random effects viK are correlated within each study
with the covariance matrix ΣK . Various assumptions can
be made about the variance-covariance matrix, which
allow for different correlations across the studies.
Consistency on the probit scale is implicit in this model.
For further details of this model, the reader is referred to
Zhang et al. [13, 24]. We will implement this model in a
Bayesian framework (see the section ‘Arm-synthesis
models in a Bayesian framework’).
Implementing the models in R
Contrast-synthesis models in a Bayesian framework
We will fit two contrast-synthesis models in a Bayesian
framework using the R package gemtc https://cran.r-
project.org/package=gemtc (Table 1). For both models,
we will fit a random-effects consistency model, with a bi-
nomial likelihood and logit link function, and a variance-
scaling factor of 2.5. We will use two different prior
distributions for the between-trial heterogeneity standard
deviation (τ): a vague prior uniform distribution, where
τeUniform 0; 10ð Þ [25] (referred to as contrast-synthesis
model 1) and an informative prior distribution (referred to
as contrast-synthesis model 2). The informative prior dis-
tribution will be selected from the predictive distributions
for between-trial variance available in Turner et al [16].
These distributions are specific to outcome types (all-cause
mortality, subjective, semi-objective) and treatment com-
parisons (pharmacological, non-pharmacological, placebo/
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control). Our networks have been classified using the same
categorisation as in Turner et al. [16]. Specifically, in the
presence of placebo in the network, the network was
categorised as pharmacological vs placebo. If only pharma-
cological treatments were available, then the network was
categorised as pharmacological vs pharmacological,
whereas if a non-pharmacological treatment was included
in the network, then the network was categorised as
non-pharmacological vs any category. For the contrast-
synthesis models 1 and 2, we will assume a common esti-
mate for the between-trial heterogeneity variance across
the different treatment comparisons [11].
Contrast-synthesis model in a frequentist framework
We will fit a contrast-synthesis model in a frequentist
framework using the R package netmeta https://cran.r-
project.org/package=netmeta (Table 1). The approach
implemented in this package is based on weighted least
squares estimation. The approach was first developed
using graph-theoretical methods that derive from elec-
trical network theory. For a detailed description of the
method and its derivation from graph-theoretical
methods, the reader is referred to Rücker [26] and Chap-
ter 8 of Schwarzer et al.’s textbook Meta-analysis with R
[27]. We refer to this model as contrast-synthesis model
3. The data will be input as contrast-level data, and the
pairwise function in the netmeta package will be used
to convert arm-level data to contrast-level data.
Arm-synthesis models in a Bayesian framework
We will fit two arm-synthesis models in a Bayesian
framework using the R package pcnetmeta https://
CRAN.R-project.org/package=pcnetmeta (Table 1). For
both models, the correlations between the random-
effects within studies are assumed equal. We will fit a
model with homogeneity of variances of the random-
effects (referred to as arm-synthesis model 1), which is
implemented by setting the model argument of pcnet-
meta equal to hom_eqcor. Next, we will fit a model with
an unstructured heterogeneous variance of the random-
effects (referred to as arm-synthesis model 2), which is im-
plemented by setting the model argument of pcnetmeta
equal to het_eqcor. We will use a uniform prior distribu-
tion for the standard deviations (σ ) of the random-effects
vik above, σ ∼Unif ormð0; 10Þ.
For the Bayesian models (i.e. contrast-synthesis models
1 and 2 and arm-synthesis models 1 and 2), three chains
will be used with a burn-in of 300,000 followed by
300,000 samples saved at an interval of 10 from each of
the three chains [28]. Convergence will be assessed by
the Brooks–Gelman–Rubin method [29, 30] and by
visual inspection of the history plots [31].
Network estimates
Analysing each NMA using the five methods described
above (contrast-synthesis models 1–3 and arm-synthesis
models 1–2), we will estimate the log of the odds ratios
and their corresponding standard errors for each pair-
wise comparison within a network; the rank of each
treatment based on the surface under the cumulative
ranking (SUCRA) curve [31]; the corresponding SUCRA
value (the p-score for the contrast-synthesis model in a
frequentist framework); and the between-trial heterogen-
eity variance for the contrast-synthesis models.
Differences in the network estimates between the
methods
We will use the following metrics to compare the net-
work estimates (described in the ‘Network estimates’
section) between the five methods:
1. Raw difference in the log of the odds ratio
2. Ratio of standard errors of the log of the odds ratios
3. Difference in rank based on the SUCRA value
4. Difference in SUCRA value
5. Ratio of the estimates of the between-trial hetero-
geneity variance for the contrast-synthesis
methods.
Exploring factors that might affect the differences in
network estimates between the methods
The differences in the estimates between the NMA
methods might be modified by several factors including
the size of the network, the rareness of events, and the
distribution of information in the network. The size of a
network and the distribution of information within a
network might be determined by the number of studies,
the number of treatments, or the number of nodes/com-
parisons, and their ratios. Therefore, we will investigate
whether the following three metrics modify the differ-
ences in the network estimates: the ratio of the number
of treatments to the number of studies, the ratio of the
number of treatments to the number of available direct
comparisons, and the ratio of the number of studies to
the number of available direct comparisons. We will also
investigate if the proportion of arms in a network with
less than 10 events modifies differences in the network
estimates.
Statistical analysis
We will begin by visually inspecting the effect estimates
and confidence/credible intervals for each pairwise com-
parison within each network (Fig. 1).
We will fit multilevel models, including random ef-
fects for network and comparison to estimate differ-
ences in the metrics (e.g. log(ORs), ranks) between
the methods. The initial model will include only a
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term for method, and additional models will include
factors hypothesised to modify differences in the net-
work estimates between the methods. We will use the
contrast-synthesis model 1 as the reference method.
Graphical methods
We will present graphical displays of the data that com-
pare network estimates between the methods (described
following). For illustrative purposes, Figs. 2, 3, and 4
depict results from simulated data, which were not
derived from or related to the networks included in our
empirical analysis.
We will graph the log of the odds ratios and 95% confi-
dence/credible interval estimated from each method for
each comparison within each of the networks. Figure 1 dis-
plays an example from a network that is not included in
our cohort. Bland-Altman plots (Fig. 2) will be presented
to assess the agreement between the estimates of the log of
the odds ratios (upper corner of Fig. 2) and standard errors
of the log of the odds ratios (lower corner of Fig. 2) using
the five methods. If there is good agreement between
Treatment 1
-.2 -.1 0 .1 .2 .3 -.6 -.5 -.4 -.3 -.2 -.3 -.2 -.1 0 -.6 -.5 -.4 -.3 -.2 -.3 -.2 -.1 0 .1 -.6 -.4 -.2 0 .2
.7 .8 .9 1 1.1 1.2
Treatment 2
-.7 -.6 -.5 -.4 -.3 -.2 -.5 -.4 -.3 -.2 -.1 0 -.8 -.6 -.4 -.2 -.4 -.3 -.2 -.1 0 -.6 -.4 -.2 0
1.2 1.4 1.6 1.8 1.2 1.4 1.6 1.8 2
Treatment 3
0 .1 .2 .3 .4 -.3 -.2 -.1 0 .1 .2 .1 .2 .3 .4 .5 -.2 0 .2 .4
1 1.1 1.2 1.3 1.4 1 1.2 1.4 1.6 .7 .75 .8 .85 .9 .95
Treatment 4
-.5 -.4 -.3 -.2 -.1 0 -.1 0 .1 .2 .3 -.3 -.2 -.1 0 .1 .2
1.2 1.4 1.6 1.8 1.2 1.4 1.6 1.8 2 2.2 .8 .9 1 1.1 1.2 1.3 1 1.2 1.4 1.6
Treatment 5
.1 .2 .3 .4 .5 -.2 0 .2 .4 .6
.9 1 1.1 1.2 1.3 1 1.1 1.2 1.3 1.4 1.5 .6 .7 .8 .9 1 .8 .9 1 1.1 1.2 .6 .7 .8 .9
Treatment 6
-.4 -.2 0 .2
1 1.2 1.4 1.6 1.8 1 1.2 1.4 1.6 1.8 .6 .8 1 1.2 .8 1 1.2 1.4 .6 .7 .8 .9 1 1.1 .8 1 1.2 1.4 1.6
Treatment 7
ln(OR)
OR
Contrast-synthesis model 1 Contrast-synthesis model 2
Contrast-synthesis model 3 Arm-synthesis model 1
Arm-synthesis model 2
Fig. 1 Log of the odds ratio and corresponding 95% confidence/credible interval for each pairwise comparison within one network. Note that
the data pictured is from a network that is not included or related to the networks in our
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methods, we would expect to see the differences between
the methods scattered around the line of no difference (i.e.,
y-axis = 0), and most of the differences lying within two
standard deviations of the mean difference [32, 33]. We
will also use Bland-Altman plots to assess the agreement
between SUCRA estimates (e.g. lower corner of Fig. 3).
To compare ranks, we will graphically display the agree-
ment between the ranks obtained from each method as a
proportion of the total number of treatments for each
rank (Fig. 4 and upper corner of Fig. 3). For example, the
first row, second column of the upper corner of Fig. 4,
shows the comparison of ranks between the contrast-
synthesis models 1 and 2. The bars in the diagonal show
the proportion of times the first and second methods
yielded the same result. In the off-diagonal, the proportion
of times the first method ranked a treatment as x and the
second method ranked that same treatment as y is
displayed (where x = 1, 2, …, 20, and y = 1, 2, …, 20, but x
≠ y). In the lower corner of Fig. 4, we show the proportion
of agreement between the methods for the first three
rankings (i.e. x = 1, 2, and 3). These plots will provide a
visual impression of the degree of agreement between the
ranks estimated from each method, with greater spread
and colour variation indicating less agreement. For ex-
ample, in Fig. 4, first row, second column, the dominance
of green bars with little variation indicates good agree-
ment in the rankings between contrast-synthesis models 1
and 2, as compared with the first row, fourth column,
where there is a lot of spread and colour variation, indicat-
ing a lack of agreement in the rankings between contrast-
synthesis model 1 and arm-synthesis model 1.
The plots will be created overall and using differ-
ent shades to identify the network characteristics
defined above.
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Fig. 2 Bland-Altman plots for the level of agreement between the log of the odds ratios (top right) and standard errors for the log of the odds
ratios (bottom left) comparing the five methods used to synthesise evidence from network meta-analyses. Note that the data pictured have been
simulated for illustrative purposes
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Discussion
To our knowledge, this will be the first empirical study
to compare a range of NMA methods applied to a large
number of networks with binary outcomes. We aim to
examine how the contrast-synthesis and arm-synthesis
models compare; how the contrast-synthesis models in a
frequentist and Bayesian framework compare; and how
the results of the contrast-synthesis (Bayesian) models
might be affected when assuming different prior distri-
butions for the between-trial heterogeneity variance.
There are several strengths of our study. We are using
a large number of networks to compare the methods.
Therefore, we will be able to conclude with reasonable
confidence whether in practice the choice of NMA
method matters (for those methods evaluated). Further,
following the lead of others [34, 35], we are publishing a
protocol of our methodological study with the aim of
clearly reporting and pre-specifying the objectives, de-
sign, and methods.
However, our study is not without limitations. We will
focus on NMA with binary outcomes, so our findings
may not be generalisable to other outcome types, such
as continuous outcomes. While we are examining five
models, many other models could be fitted, for example,
a contrast-synthesis model with random study main ef-
fects or a contrast- or arm-synthesis model with unequal
correlations between the random effects. Further, in our
evaluation of the contrast-synthesis model in a Bayesian
framework, we will use the between-trial heterogeneity
variance priors from Turner et al. [16]. For a particular net-
work, there may be a set of available priors (e.g. networks
including pharmacological and non-pharmacological inter-
ventions) and we will select the prior that has the largest
between-trial heterogeneity variance. We have chosen this
approach because it is conservative, but other choices may
impact on the findings. We are not aware of a set of prior
values based on empirical evidence that can be used to vary
the prior on the common heterogeneity variance in the
arm-synthesis models, so we have limited our investigation
of the arm-synthesis models to ones where the prior is
fixed. Finally, we will limit the dataset to networks that
demonstrate consistency. Although this consistency re-
quirement will reduce the number of included networks,
networks with identified inconsistency add to the complex-
ity of the synthesis and are beyond the scope of this empir-
ical study [4].
Fig. 3 Comparison of ranks (top right) and Bland-Altman plots for the level of agreement between the SUCRA values (bottom left) obtained
from the five methods used to synthesise evidence from network meta-analyses. Note that the data pictured have been simulated for
illustrative purposes
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The use of NMA to synthesise direct and indirect
evidence across a network of treatments is becoming
increasingly popular because of the ability to address the
important question of which treatment, from a set of
treatments, is most effective. However, there is ongoing
debate as to the most appropriate method to analyse
these networks. This research will provide evidence on
whether the choice of method in practice is important and
may usefully inform the design of future simulation studies
to investigate the performance of NMA methods.
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